SCHEMBL1704608

SCHEMBL1704608

C/C(=C\c1ccccc1)c1nc(C(=O)O)co1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.46
AKR1C3 P42330 1/20 0.42
DAGLA Q9Y4D2 4/20 0.41
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
RECQL P46063 1/20 0.37
NISCH Q9Y2I1 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
FBP1 P09467 1/20 0.36
DHODH Q02127 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1704611 1.00 CES1 (0.46) CES1AKR1C3DAGLAALDH1A1TSHR
SCHEMBL855178 0.83 KMT2A (0.47) DAGLAALDH1A1TSHRKDM4ELMNA
SCHEMBL855179 0.83 KMT2A (0.47) DAGLAALDH1A1TSHRKDM4ELMNA
SCHEMBL855180 0.83 KMT2A (0.47) DAGLAALDH1A1TSHRKDM4ELMNA
SCHEMBL1807276 0.75 CES1 (0.45) CES1DAGLAALDH1A1TSHRKDM4E
SCHEMBL22831426 0.72 CES1 (0.51) CES1AKR1C3DAGLAALDH1A1TSHR
SCHEMBL18335237 0.72 CES1 (0.49) CES1DAGLAALDH1A1TSHRKDM4E
SCHEMBL2227083 0.70 ELANE (0.43) CES1ALDH1A1TSHRRECQLKDM4E
SCHEMBL2227080 0.70 ELANE (0.43) CES1ALDH1A1TSHRRECQLKDM4E
SCHEMBL9440096 0.66 POLB (0.58) CES1AKR1C3ALDH1A1TSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440555-B1 FLUORINATED AMINOTRIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2016-05-18 EP disclosed
US-8580831-B2 Fluorinated aminotriazole derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-12 US disclosed
US-20120101138-A1 FLUORINATED AMINOTRIAZOLE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2012-04-26 US disclosed
EP-2440555-A1 FLUORINATED AMINOTRIAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143116-A1 FLUORINATED AMINOTRIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101138-A1 FLUORINATED AMINOTRIAZOLE DERIVATIVES AFF1, SULT2A1, NAT1 CES1 782/4885AKR1C3 445/4885DAGLA 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.